PubMed Health⌕ Search

PubMed · 16438569

A reversible minimum-to-minimum mapping method for the calculation of free-energy differences.

Abstract

A general method is introduced for the calculation of the free-energy difference between two systems, 0 and 1, with configuration spaces omega(0), omega(1) of the same dimensionality. The method relies upon establishing a objective mapping between disjoint subsets gamma(i)(0) of omega(0) and corresponding disjoint subsets gamma(i)(1) of omega(1), and averaging a function of the ratio of configurational integrals over gamma(i)(0) and gamma(i)(1) with respect to the probability densities of the two systems. The mapped subsets gamma(i)(0) and gamma(i)(1) need not span the entire configuration spaces omega(0) and omega(1). The method is applied for the calculation of the excess chemical potential mu(ex) in a Lennard-Jones (LJ) fluid. In this case, omega(0) is the configuration space of a (N-1) real molecule plus one ideal-gas molecule system, while omega(1) is the configuration space of a N real molecule system occupying the same volume. Gamma(i)(0) and gamma(i)(1) are constructed from hyperspheres of the same radius centered at minimum-energy configurations of a set of "active" molecules lying within distance a from the ideal-gas molecule and the last real molecule, respectively. An algorithm is described for sampling gamma(i)(0) and gamma(i)(1) given a point in omega(0) or in omega(1). The algorithm encompasses three steps: "quenching" (minimization with respect to the active-molecule degrees of freedom), "mutation" (gradual conversion of the ideal-gas molecule into a real molecule, with simultaneous minimization of the energy with respect to the active-molecule degrees of freedom), and "excitation" (generation of points on a hypersphere centered at the active-molecule energy minimum). These steps are also carried out in reverse, as required by the bijective nature of the mapping. The mutation step, which establishes a reversible mapping between energy minima with respect to the active degrees of freedom of systems 0 and 1, ensures that excluded volume interactions emerging in the process of converting the ideal-gas molecule into a real molecule are relieved through appropriate rearrangement of the surrounding active molecules. Thus, the insertion problem plaguing traditional methods for the calculation of chemical potential at high densities is alleviated. Results are presented at two state points of the LJ system for a variety of radii a of the active domain. It is shown that the estimated values of mu(ex) are correct in all cases and subject to an order of magnitude lower statistical uncertainty than values based on the same number of Widom [J. Chem. Phys. 39, 2808 (1963)] insertions at high fluid densities. Optimal settings for the new algorithm are identified and distributions of the quantities involved in it [number of active molecules, energy at the sampled minima of systems 0 and 1, and free-energy differences between subsets gamma(i)(0) and gamma(i)(1) that are mapped onto each other] are explored.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Doros N Theodorou. 2006-01-21. A reversible minimum-to-minimum mapping method for the calculation of free-energy differences.. https://doi.org/10.1063/1.2138701

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗